Curanex Pharmaceuticals Inc (CURX) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Curanex Pharmaceuticals (CURX) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Curanex is a developmental-stage pharmaceutical company developing botanical (plant-derived) drugs for inflammatory diseases, led by a candidate called Phyto-N aimed first at moderate-to-severe ulcerative colitis. The thesis is a low-cost shot at a large inflammatory-disease market using a single plant extract with a long human-use history. The biggest risks are that it is pre-revenue, pre-clinical, very thinly capitalized (about $2.9 million of cash at mid-2026), and the stock has collapsed since its 2025 IPO, needing a 1-for-20 reverse split in August 2026 to address Nasdaq's $1.00 minimum bid rule. With a market value near $7 million as of October 16, 2026, this is a highly speculative micro-cap.
CURX stock price
As of 2026-11-16, Curanex Pharmaceuticals Inc (CURX) last closed at $4.64, down 55.3% over the past year. Over the past 52 weeks it has traded between $3.66 and $10.58.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Curanex Pharmaceuticals Inc's investor relations page. Walnut is informational, not investment advice.
CURX key stats
At $4.64 on November 16, 2026, Curanex Pharmaceuticals Inc (CURX) has a market cap of $7M.
- Market cap
- $7M
- Price to book
- 1.4
Market cap, P/E and yield are measured at the $4.64 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Curanex Pharmaceuticals Inc (CURX)?
The last two weeks for Curanex Pharmaceuticals Inc, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- CURX closed at $4.64 on November 16, 2026, down 25.2% over the past five trading days (from $6.20).
- On November 13, 2026, Curanex Pharmaceuticals Inc filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Curanex Pharmaceuticals Inc (CURX) do?
Curanex Pharmaceuticals is a developmental-stage drug company that discovers and develops botanical drugs (medicines derived from plant material) to treat inflammatory diseases. Its lead candidate, Phyto-N, is an extract from a single plant with anti-inflammatory activity that the company says works through multiple biological targets and mechanisms. Curanex has reported validating Phyto-N in animal models across six inflammatory conditions, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with moderate-to-severe ulcerative colitis as the primary indication. The company has no approved products and therefore no product revenue; its path to making money depends entirely on advancing Phyto-N through clinical trials and ultimately to FDA approval, or on licensing or partnering the asset.
Curanex, headquartered in Jericho, New York, completed its initial public offering in late August 2025, selling 3,750,000 shares at $4.00 each for about $15 million in gross proceeds, and began trading on the Nasdaq Capital Market under the ticker CURX. Before the IPO its losses were small (a net loss of roughly $0.4 million in fiscal 2024), but spending has risen sharply since: the trailing twelve-month net loss through June 30, 2026 was about $10.5 million, operating cash outflow was about $12 million, and cash had fallen to roughly $2.9 million against about $0.3 million of debt. Through early 2026 the company reported preclinical progress, including a GMP-compliant pilot manufacturing batch and a dose-range-finding toxicology study with a favorable profile at the maximum dose, while guiding toward an Investigational New Drug (IND) filing for ulcerative colitis around the fourth quarter of 2026.
The stock has not held its IPO value. After trading near $0.50 in early 2026, Curanex carried out a 1-for-20 reverse stock split effective August 20, 2026, cutting shares outstanding from about 31.4 million to about 1.6 million, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. On a split-adjusted basis the $4.00 IPO price equals $80. As of October 16, 2026 the shares closed at $4.75, down about 36% year to date and about 66% over one year (though up roughly 18% over three months), for a market value of about $7.5 million. No analysts publish estimates on the stock.
What's driving Curanex Pharmaceuticals Inc (CURX)?
1. A single asset aimed at a large market.
Curanex is built almost entirely around Phyto-N, a botanical extract it positions as a multi-target anti-inflammatory. Ulcerative colitis, the lead indication, is a chronic disease with a large and growing treatment market dominated by expensive biologics. If Phyto-N ever reaches the market with a competitive profile, the addressable opportunity is large relative to the company's tiny size. That concentration also means the entire investment case rises or falls on one program.
2. Long human-use history as the differentiator.
The company emphasizes that the plant behind Phyto-N has reportedly been used in thousands of patients for inflammatory conditions over more than 30 years in China, which it frames as supportive evidence of tolerability. The botanical-drug pathway lets the FDA consider that history. This is the core narrative, but historical traditional use is not the same as controlled clinical trial data, and U.S. regulators will require rigorous studies regardless of past usage.
3. Regulatory milestones are the catalysts.
Through early 2026 Curanex advanced manufacturing, toxicology, and regulatory work toward an IND filing targeted for around the fourth quarter of 2026, which is now the quarter underway. The plan is to begin a Phase I trial roughly 30 days after the IND is accepted, then move to a Phase II study in ulcerative colitis if early results are positive. Each step is a potential catalyst, but each is also a point where the program could stall, be delayed, or fail.
4. Financing will shape the story.
The IPO brought in roughly $15 million in gross proceeds, and much of it has already been spent: cash stood near $2.9 million at June 30, 2026 after about $12 million of operating cash outflow over the prior twelve months. Clinical development is expensive, so the company will very likely need additional capital to fund trials, and raising it at a market value near $7 million could heavily dilute existing holders. How and when Curanex finances the next stages may matter as much to the stock as the science itself.
What are the risks to Curanex Pharmaceuticals Inc (CURX)?
Curanex is a pre-revenue, pre-clinical micro-cap with an unusually narrow base: a single drug candidate that has not yet entered human trials, an IND filing only targeted for late 2026, and years of clinical work and regulatory review ahead before any potential approval. Botanical drugs face the same FDA evidentiary bar as other drugs, and most early candidates never reach the market. Cash of roughly $2.9 million at mid-2026 is small next to a trailing net loss of about $10.5 million, the company has carried a going-concern style of disclosure typical of early biotechs, and it may need to raise capital on dilutive terms soon. The stock is thinly traded, has fallen about 66% over the past year, and already needed a 1-for-20 reverse split in August 2026 after receiving a Nasdaq deficiency notice, so continued weakness could bring renewed listing pressure. Holders face extreme volatility and the possibility of a total loss. Figures are approximate and drawn from public filings and market data as of October 2026.
Is CURX a buy or a sell?
We give no verdict on Curanex Pharmaceuticals Inc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. A single asset aimed at a large market. Curanex is built almost entirely around Phyto-N, a botanical extract it positions as a multi-target anti-inflammatory.
The case against. Curanex is a pre-revenue, pre-clinical micro-cap with an unusually narrow base: a single drug candidate that has not yet entered human trials, an IND filing only targeted for late 2026, and years of clinical work and regulatory review ahead before any potential approval.
Read the full bull and bear case on CURX, including what would have to change to break either one. Walnut is not an investment adviser.
Has Curanex Pharmaceuticals Inc (CURX) split its stock?
Yes. Curanex Pharmaceuticals Inc (CURX) has had one share split in the last 10 years:
- 1:20 on August 20, 2026, so every share held became 0.05 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of CURX the day before the 1:20 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Curanex Pharmaceuticals Inc (CURX) valued?
Market cap, P/E and dividend yield at today's price are in the CURX key stats above. The business figures below come from Curanex Pharmaceuticals Inc's reported results as of October 2026 and change when it next reports.
- Stage: Pre-clinical, pre-revenue
- Product revenue: $0 (no approved products)
- Net loss (TTM to Jun 2026): ~$10.5M (EPS ~-$7.80, split-adjusted)
- Cash / debt (Jun 30, 2026): ~$2.9M / ~$0.3M
- Operating cash flow (TTM): ~-$12M
- Shares outstanding (post 1-for-20 split): ~1.6M
As of October 2026: For a company like Curanex, traditional valuation metrics such as price-to-earnings or revenue multiples do not apply, because there is no revenue and the losses reflect the cost of preparing for trials. What matters is the cash runway versus the cost of clinical development, the credibility of the IND and trial timeline, and how much dilution future financings may cause. A market value near $7.5 million, about 1.4 times book value, with under $3 million of cash and a burn rate several times that, signals that the market is pricing in significant financing and execution risk rather than near-term clinical value.
Who competes with Curanex Pharmaceuticals Inc (CURX)?
Established ulcerative colitis and IBD drugmakers
Large pharma companies already sell approved therapies for ulcerative colitis and inflammatory bowel disease, including AbbVie (Rinvoq, Skyrizi), Bristol Myers Squibb (Zeposia), Pfizer (Velsipity), Takeda (Entyvio), and Eli Lilly (Omvoh). Any future Curanex product would have to compete against these entrenched, well-funded options.
Other small and clinical-stage anti-inflammatory and botanical biotechs
Curanex sits among many small clinical-stage biotechs pursuing novel anti-inflammatory and immunology mechanisms, as well as the small set of companies developing FDA-regulated botanical drugs. These peers compete for investor capital, scientific talent, and eventual market share, and most are similarly speculative and pre-profit.
ETFs and diversified alternatives
Investors who want biotech exposure without single-stock risk often use ETFs such as the SPDR S&P Biotech ETF (XBI) or the iShares Biotechnology ETF (IBB). Because Curanex is a micro-cap, it may not be included in major biotech ETFs, so broad funds offer a diversified alternative rather than direct CURX exposure.
What stocks are similar to Curanex Pharmaceuticals Inc (CURX)?
Other names that sit close to CURX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Curanex Pharmaceuticals Inc (CURX)
There are three common ways to get CURX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CURX sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where CURX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Curanex Pharmaceuticals Inc (CURX)
Curanex is a speculative, pre-clinical biotech bet on its botanical drug Phyto-N reaching the clinic and eventually the market, with no product revenue, a market value of roughly $7 million, and only a few million dollars of cash. In a portfolio it behaves like a high-risk, binary-outcome lottery ticket whose price swings on regulatory milestones and financing news rather than on earnings.
More on Curanex Pharmaceuticals Inc (CURX)
Whether CURX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CURX a buy or a sell?, and where the stock could go from here in the CURX stock forecast.
For income investors, whether CURX pays a dividend and how the payout looks is covered in does CURX pay a dividend? And to weigh CURX against a peer, read the full side-by-side comparisons: CURX vs ABBV and CURX vs BMY.
Wondering how CURX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Curanex Pharmaceuticals Inc
Ask Walnut's AI anything about CURX and see how it fits what you own.
FAQ
What does Curanex Pharmaceuticals do?
+
Curanex Pharmaceuticals is a developmental-stage drug company developing botanical (plant-derived) medicines for inflammatory diseases. Its lead candidate, Phyto-N, is a single-plant extract being developed first for moderate-to-severe ulcerative colitis, with reported activity in animal models across several other inflammatory conditions. The company has no approved products and no product revenue yet.
What is Phyto-N?
+
Phyto-N is Curanex's lead drug candidate, a botanical extract from a single plant that the company describes as having anti-inflammatory effects through multiple biological targets. The company points to a long history of traditional human use for inflammatory conditions, but Phyto-N has not yet entered U.S. clinical trials and must still be proven in controlled studies.
What stage is CURX at, and when could it have a product?
+
Curanex is at the preclinical stage. It has been targeting an Investigational New Drug (IND) filing for ulcerative colitis around the fourth quarter of 2026, with a Phase I trial planned roughly 30 days after IND acceptance and a possible Phase II study to follow. Even in a best case, FDA approval of a new drug typically takes many years, and most candidates never reach the market.
Does CURX pay a dividend?
+
No. Curanex Pharmaceuticals does not pay a dividend. It is an early, pre-revenue developmental-stage company that needs its cash to fund drug development, so any available capital goes toward operations rather than shareholder payouts.
Why has CURX stock fallen so much since its IPO?
+
Curanex priced its IPO at $4.00 per share in August 2025 but traded near $0.50 by early 2026, which led to a 1-for-20 reverse split in August 2026; on a split-adjusted basis the IPO price is $80, against a close of $4.75 on October 16, 2026. Sharp declines are common for early clinical-stage micro-caps that are pre-revenue, face long development timelines, have limited cash, and may need dilutive financing. The stock tends to move on regulatory milestones and capital-raising news rather than on earnings.
Did CURX do a reverse stock split?
+
Yes. Curanex effected a 1-for-20 reverse stock split at 12:01 a.m. Pacific Time on August 20, 2026, reducing shares outstanding from about 31.4 million to about 1.6 million. The company said the split was meant to regain compliance with Nasdaq's $1.00 minimum bid price requirement. Fractional shares were rounded up to one whole share, and the stock kept the CURX symbol with a new CUSIP.
How has CURX stock performed in 2026?
+
As of October 16, 2026, CURX closed at $4.75 (split-adjusted), down about 36% year to date and about 66% over one year. It has bounced somewhat recently, rising about 18% over three months and 8% over one month, within a 52-week range of $3.58 to $16.94. The market value is roughly $7.5 million.
Is CURX a good stock?
+
This is descriptive, not advice. The bull case is that Curanex offers a low-cost, high-upside shot at a large inflammatory-disease market if Phyto-N advances through trials and reaches approval. The bear case is that it is a pre-revenue, single-asset micro-cap with under $3 million of cash, no clinical data yet, high dilution risk, and a stock that has already lost most of its IPO value. Whether it fits depends on your own goals and risk tolerance.
Is CURX a good stock to buy right now?
+
This is informational, not a recommendation. Curanex is a highly speculative micro-cap whose value hinges on future regulatory milestones and financing rather than current results, so its price can be extremely volatile and a total loss is possible. Walnut provides information, not investment advice. Consider your time horizon, your tolerance for risk, and how a single speculative position fits your overall portfolio.
Which ETFs or baskets include CURX?
+
Because Curanex is a micro-cap that only recently went public, it is generally not held by major biotech ETFs such as XBI or IBB, which tend to weight larger companies. Investors wanting biotech exposure usually use those broad funds instead. In Walnut, you can hold CURX as one constituent of a thematic basket alongside other holdings to express a specific investment thesis.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Curanex Pharmaceuticals Inc's investor relations page or your broker before making investment decisions.